Global Hemophilia B Market Insight, Epidemiology and Market Forecast Report 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hemophilia B – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Hemophilia B – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Hemophilia B Treatment

Currently, there is no cure for hemophilia B; however, the condition can be managed with the help of available treatment choices. In order to achieve sufficient blood clotting and avoid complications associated with the condition, the basic treatment of hemophilia B is the replacement of factor IX. At present, recombinant products or products extracted from human blood or plasma are widely used to substitute factor IX to achieve an adequate amount. Apart from this, Fresh frozen plasma is also used for treatment purposes.

It is extracted from human blood and is used only when factor IX concentrate is not available to treat patients with factor IX deficiency. Currently, recombinant factor IX concentrates such as Alprolix, Benefix, Idelvion, Ixinity, Rebinyn, and Rixubis are licensed in the United States for the treatment of hemophilia B.

Apart from these, bypassing agents such as Feiba, Novoseven, and Sevenfact and human plasma-derived coagulation factor IX – AlphaNine SD and Mononine – have bagged the FDA approval as well.

Hemophilia B Epidemiology

Key Findings

In 2020, the overall prevalent cases of Hemophilia B accessed to be around 10,739 in the 7MM, which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia B epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia B, Severity-specific Prevalent Pool of Hemophilia B, Prevalent population of Hemophilia B with or without Inhibitors and Treated Prevalent Population of Hemophilia B] scenario of Hemophilia B in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.

Hemophilia B Drug Chapters

Drug chapter segment of the Hemophilia B report encloses the detailed analysis of Hemophilia B developmental stage pipeline drugs. It also helps to understand the Hemophilia B clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Hemophilia B Drugs Uptake

The current standard of care treatment for severe hemophilia B is the prophylactic intravenous replacement of coagulation factor IX (FIX) to prevent spontaneous bleeding. Persons with hemophilia without prophylactic treatment receive therapy in case of bleeding which is known as on demand treatment.

It is projected that the future of hemophilia care is going to trend toward more innovative forthcoming approaches like antibodies, siRNA, and gene therapies. In the upcoming years, the increase in hemophilia B market size is mainly driven by the introduction of pipeline candidates such as Fidanacogene elaparvovec (SPK 9001/PF-06838435), Etranacogene dezaparvovec (AMT-061), Fitusiran, Marstacimab (PF-06741086), Concizumab, FLT180a, and AMT-060 (AAV5-hFIX) during the forecast period (2021-2030).

Important areas of unmet medical need are addressed by new therapies, such as reducing the need for intravenous infusions and mitigating the risk of producing neutralizing antibodies or inhibitors. If these treatments are eventually successfully commercialized, will change the current standard of care for Hemophilia B patients. Pfizer/Spark Therapeutics’ Fidanacogene elaparvovec, uniQure’s Etranacogene dezaparvovec and Sanofi (Genzyme)/Alnylam’ Fitusiran for hemophilia B are leading towards the regulatory approval.

Access and Reimbursement Scenario in Hemophilia B Therapies

As per HAS (Haute Autorite de Sante) assessment, the last update for patients with hemophilia B was given in November 2020 (congenital factor IX deficiency). In patients of all age groups, Idelvion (albutrepenonacog alfa) is recommended and the opinion was in favor of reimbursement for the treatment and prophylaxis of patient bleeding. National Health Service (NHS) England had also agreed to reimburse this product with effect from the 20th September 2016. In addition, Alprolix (eftrenonacog alfa) was authorized for reimbursement throughout the UK in September 2016. Along with Scotland, Wales, and Northern Ireland, where Alprolix is already refunded, NHS England declared reimbursement.

Hemophilia B Marketed Drugs

• Sevenfact (coagulation factor VIIa [recombinant]-jncw): HEMA Biologics/LFB Pharmaceuticals
• Rebinyn (Nonacog beta pegol): Novo Nordisk
• Alprolix: Bioverativ Therapeutics/Sobi
• Idelvion: CSL Behring

Hemophilia B Emerging Drugs

• Concizumab: Novo Nordisk
• Fitusiran: Sanofi/Alnylam Pharmaceuticals
• Etranacogene dezaparvovec (AMT-061): CSL Behring/uniQure
• Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
• AMT-060 (AAV5-hFIX): UniQure
• Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics

Hemophilia B Pipeline Development Activities

• Etranacogene dezaparvovec (AMT-061): UniQure Biopharma B.V./ CSL Behring
• Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
• Fitusiran: Genzyme, a Sanofi Company/ Alnylam Pharmaceuticals
• Concizumab (NN7415): Novo Nordisk
• Marstacimab (PF-06741086): Pfizer
• AMT-060: UniQure Biopharma B.V.
• SerpinPC: ApcinteX Ltd
• FLT180a: Freeline Therapeutics
• SB-FIX: Sangamo Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/9qkfgu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900